NCT06801470 A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 137 participants in total. It began in 2025-01-08 with a primary completion date of 2028-01.

Brief Summary

To assess the safety, tolerability, PK and preliminary efficacy of CD-001 in patients with advanced solid tumors. and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years , regardless of gender. 2. Patients with advanced solid tumors that are histologically or cytological confirmed, lacking standard therapy, progressing after adequate standard therapy, or intolerant of standard therapy. 3. ECOG score ≤ 2. 4. At least one measurable lesion as defined by RECIST v1.1. 5. Expected survival ≥ 3 months. Exclusion Criteria: 1. Patients with known active central nervous system (CNS) and/or leptomeningeal metastases . 2. Patients who have undergone major organ surgery within 4 weeks prior to the first dosing, or who are expected to require major surgery during this study, or who have severe unhealed wounds, trauma, ulcers, etc. 3. Patients who have previously undergone a major organ transplant, bone marrow transplant, or allogeneic stem-cell transplant. 4. Patients who have a past or current history of active or chronic autoimmune disease and who have required systemic therapy within the past 2 years or is receiving systemic therapy for an autoimmune or inflammatory disease. 5. Patients who have received anti-tumor therapy within 4 weeks or 5 drug half-lives (whichever is shorter) prior to the first dosing. 6. At screening as determined by the investigator, the presence of any serious or uncontrollable disease or associated risk. 7. Patients with a history of ≥ Grade 3 (CTCAE) immune-related adverse events (irAEs) during prior anti-tumor therapy or permanent drug discontinuation due to irAEs. 8. Patients who have had a pulmonary embolism within 6 months prior to first dosing or have interstitial pneumonia at screening.

Contact & Investigator

Frequently Asked Questions

Related Trials